Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Medicine 14, 1315–1316 (1 December 2008) | doi:10.1038/nm1208-1315
Targeting RAS and PI3K in lung cancer
Abstract
Two crucial interlinked growth and survival signaling pathways have received enormous attention as targets for tumor therapy. One involves PI3K and downstream targets such as the protein kinase Akt (also known as protein kinase B).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
